Candonilimab

Generic Name: Candonilimab

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 2394841-59-7

Unique Ingredient Identifier: 6FYG1DS4NW

Background: Cadonilimab is under investigation in clinical trial NCT04220307 (A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma).

Indication: 用于既往接受含铂化疗治疗失败的复发或转移性宫颈癌患者的治疗。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Stereotactic Body Radiotherapy Combined With Cadonilimab for Advanced Refractory Malignant Solid Tumors

Phase 1

Not yet recruiting

Conditions: Safety
Advanced Solid Tumor
Stereotactic Body Radiotherapy
Immune Checkpoint Inhibitor
Efficacy

Interventions: Drug: Cadonilimab
Radiation: Stereotactic body radiotherapy

First Posted Date: 2023-06-23

Last Posted Date: 2023-06-23

Lead Sponsor: Peking University Third Hospital

Target Recruit Count: 60

Registration Number: NCT05915481

Locations: 🇨🇳
Department of radiation oncology, Peking University Third Hospital, Peking, Beijing, China

AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer

Phase 1

Recruiting

Conditions: Advanced Non-small-cell Lung Cancer

Interventions: Drug: AK112
Drug: Docetaxel
Drug: AK104
Drug: Carboplatin
Drug: paclitaxel
Drug: pemetrexed

First Posted Date: 2023-06-15

Last Posted Date: 2024-03-06

Lead Sponsor: Akeso

Target Recruit Count: 233

Registration Number: NCT05904379

Locations: 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, China
🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Cadonilimab (AK104) With or Without CT as 2rd Line Treatment for ES-SCLC

Phase 2

Recruiting

Conditions: Immunotherapy
Second-line Treatment

Interventions: Drug: Cadonilimab

First Posted Date: 2023-06-13

Last Posted Date: 2023-06-18

Lead Sponsor: Second Affiliated Hospital of Zunyi Medical University

Target Recruit Count: 30

Registration Number: NCT05901584

Locations: 🇨🇳
The Second Affiliated Hospital of Zunyi Medical University, Guizhou, ZunYi, China

Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma

Phase 1

Not yet recruiting

Conditions: Nasopharyngeal Carcinoma
Immune Checkpoint Inhibitors

Interventions: Drug: Cadonilimab
Drug: Gemcitabine
Drug: Cisplatin

First Posted Date: 2023-06-12

Last Posted Date: 2023-06-12

Lead Sponsor: Guangxi Medical University

Target Recruit Count: 20

Registration Number: NCT05898256

Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T

Phase 2

Withdrawn

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Candonilimab
Drug: Bevacizumab

First Posted Date: 2023-06-02

Last Posted Date: 2023-06-02

Lead Sponsor: Shi Ming

Registration Number: NCT05886257

Locations: 🇨🇳
Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China

TIPS Plus Cadonilimab in Advanced HCC with Tumor Thrombosis-associated Portal Hypertension:a Prospective, Single-arm, Phase II Study

Phase 2

Recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Cadonilimab
Procedure: transjugular intrahepatic portosystemic shunt (TIPS)

First Posted Date: 2023-05-31

Last Posted Date: 2024-10-16

Lead Sponsor: Fei Gao

Target Recruit Count: 30

Registration Number: NCT05882370

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer

Phase 2

Recruiting

Conditions: Pancreatic Cancer

Interventions: Drug: AK104
Drug: Gemcitabine
Drug: Oxaliplatin + Irinotecan + 5-Fluorouracil/Leucovorin
Drug: Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate
Drug: Nab-Paclitaxel

First Posted Date: 2023-05-16

Last Posted Date: 2024-12-16

Lead Sponsor: Akeso

Target Recruit Count: 78

Registration Number: NCT05859750

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳
Union Hospital Tongji Medical College Huazhong University of Science And Technology, Wuhan, Hubei, China

and more 4 locations

Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer

Phase 2

Recruiting

Conditions: Gastric Cancer

Interventions: Drug: AK104
Drug: Apatinib
Drug: Paclitaxel
Drug: S-1

First Posted Date: 2023-05-10

Last Posted Date: 2023-05-10

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 30

Registration Number: NCT05853172

Locations: 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer

Phase 2

Recruiting

Conditions: Colorectal Cancer

Interventions: Drug: cadonilimab
Drug: irinotecan
Drug: Oxaliplatin
Drug: leucovorin or levoleucovorin
Drug: 5-FU

First Posted Date: 2023-05-03

Last Posted Date: 2023-11-15

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 20

Registration Number: NCT05839470

Locations: 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China

Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint Inhibitors

Phase 2

Not yet recruiting

Conditions: Cervical Neoplasms
Uterine Cervical Neoplasms
Cancer of Cervix
Cervical Cancer
Uterine Cervical Cancer
Cancer of the Uterine Cervix

Interventions: Drug: Cadonilimab
Drug: Nab paclitaxel

First Posted Date: 2023-04-21

Last Posted Date: 2023-05-06

Lead Sponsor: Women's Hospital School Of Medicine Zhejiang University

Target Recruit Count: 58

Registration Number: NCT05824494

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy